Intellia Taps Rare Disease Veteran as CMO Amid Key Clinical Milestones
Event summary
- Intellia appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer effective October 26, 2026.
- Dr. Marantz brings 25 years of rare disease drug development experience, including successful approvals.
- She previously led the development of Scholar Rock's ISEMBYLD, the first muscle-targeted therapy for Spinal Muscular Atrophy.
- Intellia is preparing to commercialize its first in vivo gene editing product and advance Phase 3 trials for transthyretin amyloidosis.
The big picture
Intellia's appointment of Dr. Marantz underscores its push toward commercializing CRISPR-based therapies, a field that has seen significant progress but remains highly competitive. Her background in navigating complex regulatory environments and bringing rare disease treatments to market positions Intellia to potentially reset standards in gene editing. The move comes as the company prepares for critical clinical milestones, highlighting the strategic importance of leadership in translational medicine.
What we're watching
- Regulatory Strategy
- How Dr. Marantz's experience with global regulatory agencies will shape Intellia's approval pathways.
- Pipeline Acceleration
- Whether her leadership can expedite the commercialization of lonvo-z and Phase 3 trials for nex-z.
- Execution Risk
- The pace at which Intellia can translate its CRISPR technology into approved therapies under her guidance.